Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

NCT00405184 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Deficiency (PID)

Interventions

DRUG: IntragamP
DRUG: Ig NextGen 10%

Sponsor

CSL Limited